Seeking Alpha
28 Oct 2026, 11:43 UTC · 1h ago
Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued
Impact · against what's priced in
The article provides no actionable catalysts for Regeneron, as its bullish view on Dupixent and bearish view on valuation are already reflected in the current stock price. Sanofi receives a slight positive nudge from the mentioned collaboration expansion, though the overall impact is marginal.
- REGN+0.00
Already priced in
- The price assumes
A roughly 5.4% annual revenue growth rate over the next decade
The article's praise for Dupixent's 'spectacular' growth and the warning about 2031 patent cliffs are already integrated into the market's current 5.4% CAGR expectation.
What REGN's price assumes · Sep 12
